NRTI

• Minimal toxicity
• Mild GI AEs, Headache
• Renal dosing for renal insufficiency
• Severe acute exacerbation of hepatitis may occur in HBV-coinfected patients who discontinue Lamivudine/Emtricitabine therapy

NRTI

• Less GI intolerance
• Asthenia
• Acute Renal Failure, Fanconi Syndrome
• Potential for decrease in bone mineral density
• Osteomalacia
• Renal dosing

NRTI

• Hepatic dosing required
• Renal adjustments necessary
• Hypersensitivity reaction: potentially fatal

NRTI

• GI intolerance
• Asthenia
• Headache
• Myalgias
• Myelosuppression (Anemia, Neutropenia)
• Lactic Acidosis (rare)
• Renal dosing
• Neuropathy

NRTI

• Pancreatitis
• Peripheral neuropathy
• Renal dosing

NRTI

• Peripheral neuropathy
• Pancreatitis
• Lipodystrophy

• Lactic acidosis
• Lipodystrophy
• Hepatomegaly with Steatosis
• Peripheral neuropathy
• Pancreatitis
• Myopathy
• Cardiomyopathy

NNRTI

• Hepatic metabolism
• CYP3A4 drug interactions
• Rash
• Pregnancy Category D -- don't use within 1st trimester of pregnancy, women trying to conceive, and not using contraceptives
• Neuropsychiatric effects

Protease Inhibitor

• Hepatic metabolism
• Notorious for CYP3A4 drug interactions
• GI adverse effect
• Indirect hyperbilirubinemia
• Prolonged PR interval
• Hyperglycemia
• Fat maldistribution
• Possible increase bleeding episodes in patients with hemophilia
• Nephrolithiasis

Fusion Inhibitor

• Injection site reaction (pain, erythema, induration, nodules/cysts, pruritis, ecchymosis)
• Increase bacterial pneumonia
• Hypersensitivity reaction

Entry Inhibitor

• CYP450 drug interactions
• Abdominal pain, cough, dizziness, musculoskeletal symptoms, pyrexia, rash, URI, hepatoxicity, orthostatic hypotension

Integrase Strand Transfer Inhibitor

• UGT1A1-mediated glucuronidation
• Nausea, diarrhea, headache, pyrexia, CPK elevation